Brief: Chong Kun Dang Pharmaceutical receives U.S. patent
03/11/2017 06:38
Nov 3 (Reuters) - Chong Kun Dang Pharmaceutical Corp
185750.KS :
* Says it received U.S. patent on Nov. 3, for animal model
of
charcot-marie-tooth disease as hsp27 mutant(s135f) carrier
Source text in Korean: https://goo.gl/NzNqYt
Further company coverage: 185750.KS
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 010 62674724;
Reuters Messaging: hedy.cui.reuters.com@reuters.net))
Recent news on Chong Kun Dang Pharmaceutical
See all newsBrief: Chong Kun Dang Pharmaceutical Corp To Invest 392.5 Billion Won In Research Centre And Other Facility
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit 17.6 Billion Won, Up 37% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical Q3 Operating Profit 20.5 Billion Won, Down 19% From Year Earlier
Brief: Chong Kun Dang Pharmaceutical To Divest 61 Billion Won Worth Of Own Shares
Brief: Chong Kun Dang Pharmaceutical Q1 Operating Profit 12.8 Billion Won, Down 52% From Year Earlier